Halozyme withdraws $2.1 bln buyout offer for Evotec
Nov 22 (Reuters) - Halozyme Therapeutics HALO.O said
on Friday it had withdrawn its proposal to acquire Evotec SE
EVTG.DE for 2 billion euros ($2.09 billion) after the German
drug developer was unwilling to engage in discussions.
($1 = 0.9587 euros)
(Reporting by Sriparna Roy in Bengaluru; Editing by Devika
Syamnath)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Evotec SE
See all newsEvotec up 7% in early trade after 9-month revenue, earnings beat
Brief: Evotec Says Preliminary Nine-Month 2026 Results Above Market Expectations
Brief: Evotec Initiates Phase 1 Trial For Jst-018 Antibodies Targeting Orthopoxviruses
Brief: EVOTEC Q2 Group Revenues €143.50 Mln
Brief: Evotec And Odyssey Therapeutics Enter AI-Enabled R&D Collaboration In Autoimmune And Inflammatory Diseases